Acute Myeloid Leukemia — A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Citation(s)
An Open-Label Phase 2 Trial of LY2181308 Sodium Administered in Combination With Idarubicin and Cytarabine to Patients With Refractory or Relapsed Acute Myeloid Leukemia